7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Lexeo Therapeutics, Inc.
(NASDAQ:LXEO) 

LXEO stock logo

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t...

Founded: 2017
IPO Price: $11 (Nov 13, 2023)
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Lexeo Therapeutics . Op Cashflow Per Share ttm
202311 202312 202401 202402 202403 202404 -2.21-1.9-1.58-1.26-0.95-0.63-0.320
Lexeo Therapeutics . Free Cashflow Per Share ttm
202311 202312 202401 202402 202403 202404 -2.25-1.93-1.61-1.28-0.96-0.64-0.320
Lexeo Therapeutics . Cash Per Share ttm
202311 202312 202401 202402 202403 202404 00.71.392.092.793.484.184.87
Lexeo Therapeutics . P/S ratio ttm
202311 202312 202401 202402 202403 202404 084.28168.56252.84337.11421.39505.67589.95
Lexeo Therapeutics . (GAAP) P/E ratio ttm
202311 202312 202401 202402 202403 202404 -8.89-7.62-6.35-5.08-3.81-2.54-1.270
Lexeo Therapeutics . P/B ratio ttm
202311 202312 202401 202402 202403 202404 -3.35-2.47-1.58-0.690.191.081.962.85
No extra charts and metrics for this ticker.